ReviewCell adhesion & migration
What's the place of immunotherapy in malignant mesothelioma treatments?
Review in Cell adhesion & migration. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02649829 (First-line Immunotherapy Using Wilms' Tumor Protein 1), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
Who cites it
10 citing papers in PubMed, 38 citations in OpenAlex.
- Immunological subtyping of salivary gland cancer identifies histological origin-specific tumor immune microenvironment.NPJ precision oncology · 2024Article
- Article
- Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience.Thoracic cancer · 2022Article
- The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy.Frontiers in medicine · 2018Article
- Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.Journal of thoracic disease · 2017Article
- CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Oncoimmunology · 2016Article
- Current issues in malignant pleural mesothelioma evaluation and management.The oncologist · 2014Article
- Inflammation in malignant mesothelioma - friend or foe?Annals of cardiothoracic surgery · 2012Article
- Medical treatment of mesothelioma: anything new?Current oncology reports · 2011Review
- Malignant pleural mesothelioma.Current oncology reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura with a very poor prognosis. Treatments evaluated for malignant mesothelioma, including chemotherapy, radiotherapy and surgery are of limited efficacy. However, the fact that the tumors of some patients with MPM regress spontaneously or respond to immunotherapy suggests that the immune system may respond to MPM under some circumstances. In this respect, animal studies have demonstrated immunoreactivity of MPM to different immunotherapies. In the case of MPM, several clinical studies have demonstrated a correlation between the presence of a lymphocyte infiltrate and a better prognosis and humoral response directed against specific antigens related to tumor. Thus, MPM immunotherapy is undoubtedly a highly promising but also very challenging approach to the treatment of this disease that has slipped through the defense lines of the immune system. This article reviews past and recent developments of the clinical strategies that concern immunotherapy of mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.